학술논문
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Document Type
Article
Author
Bischoff, Philip; Reck, Martin; Overbeck, Tobias; Christopoulos, Petros; Rittmeyer, Achim; Lüders, Heike; Kollmeier, Jens; Kulhavy, Jonas; Kemper, Marcel; Reinmuth, Niels; Röper, Julia; Janning, Melanie; Sommer, Linna; Aguinarte, Lukas; Koch, Myriam; Wiesweg, Marcel; Wesseler, Claas; Waller, Cornelius F.; Kauffmann-Guerrero, Diego; Stenzinger, Albrecht; Stephan-Falkenau, Susann; Trautmann, Marcel; Lassmann, Silke; Tiemann, Markus; Klauschen, Frederick; Sebastian, Martin; Griesinger, Frank; Wolf, Jürgen; Loges, Sonja; Frost, Nikolaj; Hilbrandt, Moritz; Süptitz, Juliane; Grah, Christian; Velthaus, Janna-Lisa; Kopp, Hans-Georg; Schmidt, Bernd; Horter, Susanne; Keymel, Stefanie; Aydilek, Enver; Tritchkova, Guergana; Raspe, Matthias; Papić, Dražen; Florian, Stefan; Horst, David; Wild, Peter J.; Thomas, Michael; Grohé, Christian; Bleckmann, Annalen; Wermke, Martin; Hummel, Horst-Dieter; Stratmann, Jan; Schütte, Wolfgang
Source
Journal of Thoracic Oncology; 20240101, Issue: Preprints
Subject
Language
ISSN
15560864; 15561380
Abstract
Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing responses. Assessment of KRASand TP53mutations (mut) as surrogate for an immunosupportive tumor microenvironment (TME) might help to close this gap.